Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAVAR-2 phase II dose-ranging study of HJY-ATRQβ-001 in mild to moderate hypertension
ChiCTR2600135587Phase 2Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Nov 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HJY-ATRQβ-001 in essential hypertension (5 arms), sponsored by Union Hospital. Primary endpoints: Seated blood pressure and 24-hour ambulatory blood pressure monitoring. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
HJY-ATRQβ-001
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2600135587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135587.